Latest News
-
Rs 8.50/Share Dividend Recommended: Nestle India Reports 27% YoY Jump In Profit -
0.50% Dividend Yield: Midcap Cement Stock Slumps 10% Following Weak Q4 Results; Profit Down 48% YoY -
1:10 Split, Rs 147/Share Dividend: FMCG Major Likely To Report Profit Growth; Buy Or Sell? -
Mark Zuckerberg's Meta Reports Record Q1 Profit Surge, Projects AI Investments This Year; Stock Slumps -
Gold Prices India: 24K/100 Grams Yellow Metal Falls By Rs 3800, 24K/10 Grams Down By Rs 380 -
Rs 44,000 Crore M-Cap Lost, Stock Falls 10%, No More 4th Largest Bank; How RBI's Ban Rocked Kotak -
Mukesh Ambani Led JioCinema Slashes Premium Subscription Prices; IPL Live Stream Remains Free -
Strong Listing: Vodafone Idea FPO Soars In Debut, Shares Rebound; KM Birla Lauds Success -
JPMorgan CEO Jamie Dimon Hails PM Modi's Economic Reforms, Urges US to Follow Suit; Details -
Rs. 60/Share Dividend: Record Date On 28 June; Buy The Bajaj Group Stock For 600% Payout?
This Multibaggaer Small Cap Pharma Stock Fixes Record Date For 400% Dividend This Week
A tumultuous year for dividend stocks is proving to be another exciting month for dividend investment stocks. The best strategy is to invest in dividend equities to increase passive income. Your monthly expenses will eventually be covered by dividend income. Because of this, investors are constantly looking for undervalued dividend stocks to purchase. to invest their hard-earned money.
AstraZeneca Pharma India Ltd, a small-cap pharma company declared a final dividend in May, now that the final dividend is turning ex-ex-dividend this week. The record date is also announced. Should you buy the stock? Let's find out!
400% Final Dividend
The Board of Directors of AstraZeneca Pharma India Ltd at its board meeting held on May 26, 2022, declared a final dividend of 400% amounting to Rs 8 per equity share for FY 21-22.
The board of directors in its filing to BSE and NSE has said, "Recommended Final Dividend of Rs. 8/- per equity share for the financial year 2021-22."
Ex-Dividend Date & Record Date - Investors should note, the ex-dividend date of the declared final dividend is 07 July 2022 and the record date is 08 July 2022.
Dividend History of AstraZeneca
AstraZeneca Pharma India Ltd. has a good track record of dividends as it has declared 17 dividends since Aug. 11, 2000. These 17 declared dividends include 4 Interim Dividends and the rest 13 final dividends. In 2021, the company declared a 100% interim dividend amounting to Rs 2 per equity share.
Stock Outlook & Returns
04 July 2022, On NSE, the shares of the company closed at Rs 2,742.05 per share after gaining 1.10%. It was opened at Rs 2,719.85 per share. The stock's 52-week low per share level is Rs 2,445.70, while the 52-week high per share level is Rs 3,675. In May, this year the stock hit the 52-week low, while the 52-week high was hit last year on July 6. With a market cap of Rs 6,855.13 crore, it is a small-cap stock.
PE ratio is 111.30, while the PB ratio is 13.30. The EPS-TTM is Rs 24.64. ROE is 12.04%. The stock in the past 1 year has declined by nearly 23.65%. In the past 3 years, it has gained 29.24%, giving positive returns. In 5 years it gave a multibagger return of 199.43%.
About - AstraZeneca Pharma India Ltd.
AstraZeneca India was established in 1979 and is headquartered in Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is an operating company and covers the manufacturing, sales and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. It has a workforce of over 1400 employees across the country that is committed to delivering life-changing medicines to patients through innovative science and global excellence in development and commercialization. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory.
Disclaimer
The stock has been sourced from NSE & BSE. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
